NetworkNewsBreaks – Pressure BioSciences Inc. (P
Post# of 1354
(Total Views: 175)
Posted On: 07/24/2019 3:26:27 PM
NetworkNewsBreaks – Pressure BioSciences Inc. (PBIO) Announces Second Major Contract Utilizing its BaroFold Technology Platform
Pressure BioSciences (OTCQB: PBIO), a leader in the development and sale of broadly enabling, pressure-based technology and products to the worldwide life sciences and other industries, today announced its entry into a contract services agreement with a multi-billion biotherapeutics company to enhance the manufacturing process of one of their candidate protein drugs. Per the update, the manufacturing of therapeutic proteins can be a complex and challenging process, and PBI’s BaroFold(TM) technology platform offers a unique and cost-effective way to address major challenges. “The BaroFold platform can be applied to the development and production of many different therapeutic proteins, can improve product safety, and is scalable and practical for standard bioprocess environments,” PBIO Chief Science Officer Dr. Alexander Lazarev said in the news release. “Moreover, it offers ways to reduce or eliminate the use of aggressive chemicals in the protein manufacturing process. Thus, we believe this unique technology platform can help biopharmaceutical companies create and manufacture high quality novel protein therapeutics and biosimilars, lower the cost of existing formulations, and help protect our environment.”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
Pressure BioSciences (OTCQB: PBIO), a leader in the development and sale of broadly enabling, pressure-based technology and products to the worldwide life sciences and other industries, today announced its entry into a contract services agreement with a multi-billion biotherapeutics company to enhance the manufacturing process of one of their candidate protein drugs. Per the update, the manufacturing of therapeutic proteins can be a complex and challenging process, and PBI’s BaroFold(TM) technology platform offers a unique and cost-effective way to address major challenges. “The BaroFold platform can be applied to the development and production of many different therapeutic proteins, can improve product safety, and is scalable and practical for standard bioprocess environments,” PBIO Chief Science Officer Dr. Alexander Lazarev said in the news release. “Moreover, it offers ways to reduce or eliminate the use of aggressive chemicals in the protein manufacturing process. Thus, we believe this unique technology platform can help biopharmaceutical companies create and manufacture high quality novel protein therapeutics and biosimilars, lower the cost of existing formulations, and help protect our environment.”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
(0)
(0)